The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis
- PMID: 22333132
- PMCID: PMC3312864
- DOI: 10.1186/1471-2466-12-3
The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis
Abstract
Background: In cystic fibrosis (CF) patients, it has been suggested that systemic inflammation may be an important risk factor for poor health outcomes. The relationship of plasma inflammatory biomarkers to lung function and hospitalization history remains largely unexplored.
Methods: This cross-sectional study included 58 consecutive, clinically stable adults from the CF Clinic at St. Paul's Hospital (Vancouver, Canada). Blood levels of interleukin (IL)-6, IL-1β, C-reactive protein (CRP), interleukin (IL)-6, IL-1β, granzyme B (GzmB), chemokine C-C motif ligand 18 (CCL18/PARC), surfactant protein D (SP-D), lipopolysaccharide (LPS)-binding protein, and soluble cluster of differentiation 14 (sCD14) were measured using enzyme-linked immunosorbent assays, and LPS levels were measured using a Limulus amebocyte lysate assay. Spirometry was also performed. Multivariable linear regression analysis was used to assess relationships of the blood biomarkers to lung function.
Results: Lung function impairment was independently associated with elevated plasma levels of CRP (P < 0.01), IL-6 (P = 0.04), IL-1β (P < 0.01), and LBP (P < 0.01). Increasing age (P < 0.01), reduced body mass index (P = 0.02), prior hospitalizations (P = 0.03), and presence of Pseudomonas aeruginosa in sputum cultures (P < 0.01) were also associated with reduced lung function. Elevated concentrations of LPS in plasma were associated with a previous history of hospitalization (P < 0.05). There was a trend towards an increase in plasma IL-6 (P = 0.07) and IL-1β (P = 0.06) levels in patients who were previously hospitalized.
Conclusions: IL-6 and IL-1β are promising systemic biomarkers for lung function impairment and history of hospitalization in adult patients with CF.
Figures


Similar articles
-
Serum Lipopolysaccharide-Binding Protein is Associated with Chronic Inflammation and Metabolic Syndrome in Hemodialysis Patients.Blood Purif. 2019;47(1-3):28-36. doi: 10.1159/000492778. Epub 2018 Sep 14. Blood Purif. 2019. PMID: 30219816 Clinical Trial.
-
Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.PLoS One. 2014 Feb 20;9(2):e89341. doi: 10.1371/journal.pone.0089341. eCollection 2014. PLoS One. 2014. PMID: 24586701 Free PMC article.
-
High-mobility group box-1 protein, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in children with community acquired infections and bacteraemia: a prospective study.BMC Infect Dis. 2010 Feb 16;10:28. doi: 10.1186/1471-2334-10-28. BMC Infect Dis. 2010. PMID: 20158885 Free PMC article.
-
Blood concentrations of lipopolysaccharide-binding protein, high-sensitivity C-reactive protein, tumor necrosis factor-α, and Interleukin-6 in relation to insulin resistance in young adolescents.Clin Chim Acta. 2018 Nov;486:115-121. doi: 10.1016/j.cca.2018.07.042. Epub 2018 Jul 29. Clin Chim Acta. 2018. PMID: 30059659
-
Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases.Biomolecules. 2021 Oct 5;11(10):1464. doi: 10.3390/biom11101464. Biomolecules. 2021. PMID: 34680097 Free PMC article. Review.
Cited by
-
Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase.PLoS One. 2013 Sep 30;8(9):e75667. doi: 10.1371/journal.pone.0075667. eCollection 2013. PLoS One. 2013. PMID: 24098711 Free PMC article.
-
ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor-ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis-an observational study.BMJ Open Respir Res. 2023 May;10(1):e001590. doi: 10.1136/bmjresp-2022-001590. BMJ Open Respir Res. 2023. PMID: 37130650 Free PMC article.
-
Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.Pediatr Pulmonol. 2017 Nov;52(S48):S21-S28. doi: 10.1002/ppul.23768. Epub 2017 Jul 17. Pediatr Pulmonol. 2017. PMID: 28714611 Free PMC article. Review.
-
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis.Clin Transl Sci. 2017 Jan;10(1):28-34. doi: 10.1111/cts.12428. Epub 2016 Nov 2. Clin Transl Sci. 2017. PMID: 27806191 Free PMC article. Clinical Trial.
-
Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.Front Immunol. 2023 Feb 16;14:1107437. doi: 10.3389/fimmu.2023.1107437. eCollection 2023. Front Immunol. 2023. PMID: 36875141 Free PMC article.
References
-
- Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2009 Annual Data Report. Bethesda, MD; 2011.
-
- Ionescu AA, Nixon LS, Evans WD, Stone MD, Lewis-Jenkins V, Chatham K, Shale DJ. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med. 2000;162(3 Pt 1):789–794. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous